Friday, July 10, 2026
🇺🇸 FDA

pharma · Hemophagocytic lymphohistiocytosis (HLH) · Multiple sclerosis

PARItec

Pari Pharma GmbH

PARItec clinical programs — 248 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
Starnberg, DE HQ
28 Employees
EMA registrant Type
Company details
Status
Public
HQ
Starnberg, DE
Employees
28
Programs
248
Drugs
362
Patents
0
Official website ↗ All projects Drug pipeline News & analysis
Intelligence · Clinical Programs

PARItec projects

248 ClinicalTrials.gov programs sponsored by PARItec.

PARItec has 248 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

248 programs

Clinical programs

Page 1 of 6

  1. 0.9% Sodium Chloride Solution, Glenzocimab

    Pari Pharma GmbH

    Acute ischemic stroke

    phase 3 small molecule active

    1 trial

  2. 18F-DPA-714

    Pari Pharma GmbH

    Multiple sclerosis

    phase 3 small molecule active

    1 trial

  3. 2025-521093-34-00

    Pari Pharma GmbH

    rare disease

    phase 3 small molecule active

    1 trial

  4. AMIKACIN

    Pari Pharma GmbH

    Adult patients admitted to intensive care

    phase 3 small molecule active

    1 trial

  5. APHP 180610

    Pari Pharma GmbH

    Acute Myocardial Infarction

    phase 3 small molecule active

    1 trial

  6. APHP 180610

    Pari Pharma GmbH

    Acute Myocardial Infarction

    phase 3 small molecule active

    1 trial

  7. APHP 200040

    Pari Pharma GmbH

    Acute kidney injury

    phase 3 small molecule active

    1 trial

  8. APHP 230842

    Pari Pharma GmbH

    patients with chronic respiratory insufficiency due to amyotrophic lateral sclerosis.

    phase 3 small molecule active

    1 trial

  9. APHP180560

    Pari Pharma GmbH

    Men and women over 18 years of age with renal failure renal failure stages 3b/4/5, renal transplantation or dialysis and an untreated gout attack

    phase 3 small molecule active

    1 trial

  10. APHP180583

    Pari Pharma GmbH

    Severe Irritable Bowel Syndrome (IBS)

    phase 3 small molecule active

    1 trial

  11. APHP180584

    Pari Pharma GmbH

    patients with acute respiratory failure from undetermined etiology

    phase 3 small molecule active

    1 trial

  12. APHP180587

    Pari Pharma GmbH

    Patients colonized with MDR-GNB

    phase 3 small molecule active

    1 trial

  13. APHP180588

    Pari Pharma GmbH

    early syphilis

    phase 3 small molecule active

    1 trial

  14. APHP180591

    Pari Pharma GmbH

    Adults Non Diabete Remission (NDR) Type 2 Diabete (T2D) patients 1 to 5 years after bariatric surgery

    phase 3 small molecule active

    1 trial

  15. APHP180592

    Pari Pharma GmbH

    Diseases [C] - Virus Diseases [C02]

    phase 3 small molecule active

    1 trial

  16. APHP180596

    Pari Pharma GmbH

    antibiotic therapy in Sepsis

    phase 3 small molecule active

    1 trial

  17. APHP180605

    Pari Pharma GmbH

    Excision-autograft surgery in burn patient

    phase 3 small molecule active

    1 trial

  18. APHP180612

    Pari Pharma GmbH

    Dermatomyositis; Baricitinib in patients with relapsing or naïve dermatomyositis.

    phase 3 small molecule active

    1 trial

  19. APHP180668

    Pari Pharma GmbH

    primary sclerosing cholangitis

    phase 3 small molecule active

    1 trial

  20. APHP191047

    Pari Pharma GmbH

    Patients with microcirculatory abnormalities during septic shock

    phase 3 small molecule active

    1 trial

  21. APHP191099

    Pari Pharma GmbH

    Patients hospitalised in intensive care, diagnosed with sepsis less than 48 hours ago, uric acid level ≥200µmol/L, adults, negative G6PD deficiency

    phase 3 small molecule active

    1 trial

  22. APHP191105

    Pari Pharma GmbH

    Sarcoidosis

    phase 3 small molecule active

    1 trial

  23. APHP191110

    Pari Pharma GmbH

    Patients admitted to the ICU proven or suspected infection as the main diagnosis.

    phase 3 small molecule active

    1 trial

  24. APHP200009

    Pari Pharma GmbH

    Kawasaki disease

    phase 3 small molecule active

    1 trial

  25. APHP200011

    Pari Pharma GmbH

    Intensive care, Ventilator Associated Pneumonia

    phase 3 small molecule active

    1 trial

  26. APHP200017

    Pari Pharma GmbH

    Adult patients with immune thrombocytopenia (ITP) with mild to severe bleeding manifestations

    phase 3 small molecule active

    1 trial

  27. APHP200018

    Pari Pharma GmbH

    Critically ill patients suffering from CIRCI

    phase 3 small molecule active

    1 trial

  28. APHP200019

    Pari Pharma GmbH

    Patient with sepsis complicated by ARDS

    phase 3 small molecule active

    1 trial

  29. APHP200026

    Pari Pharma GmbH

    Patients with GPA and inadequate response to standard of care therapy defined as an inadequate response to either a combination of glucocorticoids plus cyclophosphamide AND/OR a combination of glucocorticoids plus rituximab.

    phase 3 small molecule active

    1 trial

  30. APHP200031

    Pari Pharma GmbH

    Adult women with recurrent implantation failures (RIF)

    phase 3 small molecule active

    1 trial

  31. APHP200038

    Pari Pharma GmbH

    lupus nephritis

    phase 3 small molecule active

    1 trial

  32. APHP200043

    Pari Pharma GmbH

    Hemoptysis, whatever the cause, with the exception of cystic fibrosis

    phase 3 small molecule active

    1 trial

  33. APHP200046

    Pari Pharma GmbH

    HPV vaccine

    phase 3 small molecule active

    1 trial

  34. APHP200056

    Pari Pharma GmbH

    Remyelination in Multiple Sclerosis

    phase 3 other active

    1 trial

  35. APHP200068

    Pari Pharma GmbH

    Adult ICU patients with septic shock

    phase 3 small molecule active

    1 trial

  36. APHP200072

    Pari Pharma GmbH

    Patients referred for an isolated or a combined surgical correction of functional moderate to severe tricuspid regurgitation

    phase 3 small molecule active

    1 trial

  37. APHP200073

    Pari Pharma GmbH

    Erythema multiforme (EM) in its severe form managed at the hospital

    phase 3 small molecule active

    1 trial

  38. APHP201098

    Pari Pharma GmbH

    Adult patients with persistent or chronic immune thrombocytopenia

    phase 3 small molecule active

    1 trial

  39. APHP210089

    Pari Pharma GmbH

    Patients hospitalized for allogeneic hematopoietic stem cell transplantation

    phase 3 small molecule active

    1 trial

  40. APHP210090

    Pari Pharma GmbH

    Adult patients admitted to the ICU for management of severe influenza infection requiring orotracheal intubation for invasive mechanical ventilation

    phase 3 small molecule active

    1 trial

  41. APHP211003

    Pari Pharma GmbH

    Primary Bilateral Macronodular Adrenal Hyperplasia causing moderate Cushing Syndrome (Mild autonomous Cortisol secretion)

    phase 3 small molecule active

    1 trial

  42. APHP211034

    Pari Pharma GmbH

    patients hospitalized in ICU with ESBL-producing Enterobacteriaceae severe infection

    phase 3 small molecule active

    1 trial

  43. APHP211035

    Pari Pharma GmbH

    vaso-occlusive crisis due to sickle cell disease

    phase 3 small molecule active

    1 trial

  44. APHP211043

    Pari Pharma GmbH

    acute pyelonephritis (AP) in children

    phase 3 small molecule active

    1 trial

  45. APHP211044

    Pari Pharma GmbH

    urgency, limb injuries

    phase 3 small molecule active

    1 trial

  46. APHP211046

    Pari Pharma GmbH

    Any patients ≥18 years old, eligible for transfemoral TAVI with coverage for medical insurance

    phase 3 small molecule active

    1 trial

  47. APHP211053

    Pari Pharma GmbH

    Primary Sclerosing Cholangitis

    phase 3 small molecule active

    1 trial

  48. APHP211057

    Pari Pharma GmbH

    myelin oligodendrocytes glycoprotein antibody associated diseases (MOGAD)

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does PARItec have?

248 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.